Further, our data from experiments with multiple primary KRAS G12C inhibition‐resistant cancer models showed elevated YAP activity upon AMG510 treatment and significant reductions in the extent of YAP activation upon the combination treatment (AMG510 and IN10018). Here, KRAS is linked to cancer.